Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Arbutus Biopharma Corp ABUS

Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company. The Company is leveraging its virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can potentially be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV) infection. Its HBV product pipeline includes Imdusiran and AB-101. Imdusiran is its proprietary, conjugated GalNAc, subcutaneously delivered RNAi therapeutic product candidate. AB-101 is an oral PD-L1 inhibitor that has the potential to reawaken patients’ HBV-specific immune response by inhibiting PD-L1. Its pipeline includes two product candidates that target various steps in the HBV viral lifecycle and consists of various programs: RNAi therapeutic (imdusiran, AB-729) and Oral PD-L1 Inhibitor (AB-101). RNAi therapeutics utilize a natural pathway within cells to silence genes by eliminating the disease-causing proteins that they code for.


NDAQ:ABUS - Post by User

Bullboard Posts
Comment by seeingeyeon Nov 29, 2011 12:33pm
344 Views
Post# 19274964

RE: Fox in the Henhouse

RE: Fox in the Henhouse
Try Again. Lawsuit is gonna pay huge IMO as ALNY continues to prove they are teckno bandits.
What does the board think ????
***************************************************************************************************

Tekmira Files for an Injunction in the Supreme Court of British Columbia Seeking Return of Confidential Documents
Tekmira Files for an Injunction in the Supreme Court of British Columbia Seeking Return of Confidential Documents

VANCOUVER, British Columbia, Nov. 16, 2011 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, disclosed today that it has filed a Notice of Civil Claim in the Supreme Court of British Columbia against certain individuals from AlCana Technologies, Inc. ("AlCana") alleging that thousands of confidential documents containing Tekmira's confidential information and trade secrets were downloaded and taken from Tekmira. Tekmira also filed a Notice of Application seeking an injunction ordering the documents and derivative materials be returned to Tekmira.

Tekmira discovered the alleged document downloading in the course of producing documents in Tekmira's litigation against Alnylam Pharmaceuticals, Inc. and AlCana in the Massachusetts Superior Court.

In its action, Tekmira alleges that over 10,000 documents containing Tekmira's confidential information and trade secrets were downloaded from Tekmira's electronic document management system and used by AlCana to produce lipids belonging to Tekmira, including the lipid MC3. Tekmira is seeking a pre-trial and permanent mandatory injunction ordering the defendants to surrender all confidential information belonging to Tekmira and an injunction prohibiting the defendants from using or disclosing Tekmira's confidential information to any person or corporation. Tekmira is also seeking general and punitive damages.

Bullboard Posts